💊 Buprenorphine (Buprenorphine)
Buprenorphine sublingual tablets are indicated for the treatment of opioid dependence and are preferred for induction. They should be used as part of a complete treatment plan that includes counseling and psychosocial support.
In Arabic: بوبرينورفين🏷️ Brand names & manufacturers
Packages shown are US-market (DailyMed). Brands available in Palestine are in the price section below.✅ What it is used for
- Treatment of opioid dependence
- Preferred for induction
- Use as part of a complete treatment plan that includes counseling and psychosocial support
🧪 Active ingredient
Buprenorphine: a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor.
🌿 Benefits
- Treatment of opioid dependence
- Preferred for induction
- Used as part of a complete treatment plan including counseling and psychosocial support
📝 How to use
- Administer sublingually as a single daily dose
- Must be administered whole; do not cut, chew, or swallow
- Induction should be undertaken when objective and clear signs of withdrawal are evident to avoid precipitating withdrawal
- When discontinuing treatment, gradually taper to avoid withdrawal signs and symptoms
💊 Dosage forms
- Uncoated orange oval sublingual tablets, buprenorphine 2 mg
- Uncoated orange oval sublingual tablets, buprenorphine 8 mg
⚠️ Common side effects
- Oral hypoesthesia
- Glossodynia
- Oral mucosal erythema
- Headache
- Nausea
- Vomiting
- Hyperhidrosis
- Constipation
- Signs and symptoms of withdrawal
- Insomnia
- Pain
- Peripheral edema
🚨 Serious — seek medical help
- Addiction, abuse, and misuse
- Respiratory and CNS depression
- Neonatal opioid withdrawal syndrome
- Adrenal insufficiency
- Opioid withdrawal
- Hepatitis, hepatic events
- Hypersensitivity reactions
- Orthostatic hypotension
- Elevation of cerebrospinal fluid pressure
- Elevation of intracholedochal pressure
⛔ Do not use if
- History of hypersensitivity to buprenorphine (serious adverse reactions, including anaphylactic shock, have been reported)
❗ Warnings & precautions
- Buprenorphine can be abused in a similar manner to other opioids; monitor for conditions indicative of diversion or progression of opioid dependence and addictive behaviors
- Life-threatening respiratory depression and death have occurred with buprenorphine use; warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants
- Store safely out of the sight and reach of children; buprenorphine can cause severe, possibly fatal, respiratory depression in children
- Neonatal opioid withdrawal syndrome is an expected and treatable outcome of prolonged opioid use during pregnancy
- If adrenal insufficiency is diagnosed, treat with physiologic replacement of corticosteroids and wean the patient off the opioid
- If treatment is temporarily interrupted or discontinued, monitor patients for withdrawal and treat appropriately
- Monitor liver function tests prior to initiation and during treatment and evaluate suspected hepatic events
- An opioid withdrawal syndrome is likely with parenteral misuse or sublingual administration before the agonist effects of other opioids have subsided
- Not appropriate as an analgesic; deaths have been reported in opioid-naïve individuals who received a 2 mg sublingual dose
🔄 Drug interactions
- Benzodiazepines or other CNS depressants, including alcohol: increase the risk of respiratory depression, profound sedation, coma, and death
- CYP3A4 inhibitors: can increase plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects
🤰 Pregnancy
Data on use of buprenorphine in pregnancy are limited; however, these data do not indicate an increased risk of major malformations specifically due to buprenorphine exposure. There are limited data from randomized clinical trials in women maintained on buprenorphine that were not designed appropriately to assess the risk of major malformations. Observational studies have reported congenital malformations among buprenorphine-exposed pregnancies but were also not designed appropriately. Reproductive and developmental studies in rats and rabbits identified adverse events at clinically relevant and higher doses. Based on animal data, advise pregnant women of the potential risk to a fetus.
🍼 Breastfeeding
Buprenorphine passes into mother's milk. Based on two studies in 13 lactating women, buprenorphine and its metabolite norbuprenorphine were present in low levels in human milk and available data have not shown adverse reactions in breastfed infants. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need and any potential adverse effects on the breastfed child. Advise breastfeeding women to monitor the infant for increased drowsiness and breathing difficulties.
🧒 Children
The safety and effectiveness of buprenorphine sublingual tablets have not been established in pediatric patients.
👴 Older adults
Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. Due to possible decreased hepatic, renal, or cardiac function and concomitant disease or other drug therapy, prescribe cautiously in individuals 65 years of age or older and monitor for signs and symptoms of toxicity or overdose.
🌡️ Storage
Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F). Dispense in a tight, light-resistant container. Store securely and dispose of properly.
🆘 Overdose
Manifestations of acute overdose include pinpoint pupils, sedation, hypotension, hypoglycemia, respiratory depression, and death. Monitor respiratory and cardiac status carefully; when depressed, re-establish adequate respiratory exchange through a patent airway and assisted or controlled ventilation. Oxygen, IV fluids, vasopressors, and other supportive measures should be employed as indicated. An opioid overdose reversal agent may be of value; higher than normal doses and repeated administration may be necessary. Consider the long duration of action of buprenorphine when determining the length of treatment and medical surveillance.
💰 Price & brands in your area
Local prices are currently available for Palestine; more countries are coming. Ask your pharmacist for local price and alternatives.
📍 Find the nearest pharmacy
Your location is used only in your browser to show nearby pharmacies — we don't store it.
Open in Google Maps👨⚕️ For healthcare professionals
Mechanism of action
Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor.
Labeled dosing
Administer sublingually as a single daily dose. Induction should be undertaken when objective and clear signs of withdrawal are evident. Buprenorphine and naloxone sublingual film or tablet is generally initiated after two days of buprenorphine sublingual tablets titration. Administer tablets whole; do not cut, chew, or swallow. When discontinuing treatment, gradually taper.
- Strongly consider recommending or prescribing an opioid overdose reversal agent (e.g., naloxone, nalmefene) when initiating or renewing treatment
- Following induction, buprenorphine and naloxone sublingual film or tablet is preferred due to the presence of naloxone when clinical use includes unsupervised administration
- Use of buprenorphine sublingual tablets for unsupervised administration should be limited to patients who cannot tolerate buprenorphine and naloxone sublingual film or tablet, e.g., those hypersensitive to naloxone
- Prescribe in consideration of the frequency of visits; multiple refills are not advised early in treatment or without appropriate follow-up visits
- Severe hepatic impairment: consider reducing the starting and titration incremental dose by half and monitor for signs and symptoms of toxicity or overdose
- Geriatric patients: monitor for sedation or respiratory depression
🎓 Key points for students
- Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor
- The sublingual tablets do not contain naloxone and are preferred for use only during induction
- Buprenorphine produces typical opioid agonist effects which are limited by a ceiling effect
- Tablets must be administered whole; do not cut, chew, or swallow
- Buprenorphine is a Schedule III controlled substance
EME runs your whole clinic: appointments with WhatsApp reminders, patient files, finance & inventory, a patient portal and a members-price medical store — with your data isolated and protected.
Try EME free How we protect your data❓ FAQ
How do I take buprenorphine sublingual tablets?
Administer sublingually as a single daily dose. The tablet must be taken whole; do not cut, chew, or swallow it. The dose is set by the doctor or pharmacist.
Can buprenorphine cause withdrawal?
Yes, an opioid withdrawal syndrome is likely with parenteral misuse or with sublingual administration before the agonist effects of other opioids have subsided; induction should be undertaken when objective and clear signs of withdrawal are evident.
What are the most important drug interactions?
Benzodiazepines or other CNS depressants, including alcohol, increase the risk of respiratory depression, profound sedation, coma, and death. CYP3A4 inhibitors can increase buprenorphine plasma concentrations.
Can it be used during pregnancy or breastfeeding?
Pregnancy data are limited but do not indicate an increased risk of major malformations specifically due to buprenorphine; advise pregnant women of the potential risk to a fetus. Buprenorphine passes into mother's milk at low levels; advise breastfeeding women to monitor the infant for increased drowsiness and breathing difficulties.
What should I do in case of overdose?
Manifestations include pinpoint pupils, sedation, hypotension, hypoglycemia, and respiratory depression. Seek emergency medical help; treatment includes monitoring respiratory and cardiac status and re-establishing adequate ventilation, and an opioid overdose reversal agent may be of value.
⚕️ For education only — not a substitute for advice from your doctor or pharmacist. Do not start or stop any medicine without advice. Source: official FDA drug label via openFDA (2026-05), simplified. Updated: 2026-11-16.
Brixadi🏭 Braeburn Inc.
Sublocade🏭 Indivior Inc.
Butrans🏭 Knoa Pharma LLC
Buprenorphine Transdermal System🏭 Alvogen Inc.
Buprenorphine🏭 Actavis Pharma, Inc.
Buprenorphine🏭 AvPAK